HEADER TRANSFERASE 26-FEB-18 6FU5 TITLE STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE TITLE 2 INHIBITOR CSLP18 COMPND MOL_ID: 1; COMPND 2 MOLECULE: RECEPTOR-INTERACTING SERINE/THREONINE-PROTEIN KINASE 2; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: CARD-CONTAINING INTERLEUKIN-1 BETA-CONVERTING ENZYME- COMPND 5 ASSOCIATED KINASE,CARD-CONTAINING IL-1 BETA ICE-KINASE,RIP-LIKE- COMPND 6 INTERACTING CLARP KINASE,RECEPTOR-INTERACTING PROTEIN 2,RIP-2, COMPND 7 TYROSINE-PROTEIN KINASE RIPK2; COMPND 8 EC: 2.7.11.1,2.7.10.2; COMPND 9 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: RIPK2, CARDIAK, RICK, RIP2, UNQ277/PRO314/PRO34092; SOURCE 6 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 7 EXPRESSION_SYSTEM_COMMON: FALL ARMYWORM; SOURCE 8 EXPRESSION_SYSTEM_TAXID: 7108 KEYWDS TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR D.M.PINKAS,J.C.BUFTON,K.KUPINSKA,N.A.BURGESS-BROWN,F.VON DELFT, AUTHOR 2 C.H.ARROWSMITH,A.M.EDWARDS,C.BOUNTRA,A.N.BULLOCK REVDAT 5 17-JAN-24 6FU5 1 REMARK REVDAT 4 12-SEP-18 6FU5 1 JRNL REVDAT 3 29-AUG-18 6FU5 1 HEADER KEYWDS REVDAT 2 01-AUG-18 6FU5 1 JRNL REVDAT 1 25-APR-18 6FU5 0 JRNL AUTH M.HRDINKA,L.SCHLICHER,B.DAI,D.M.PINKAS,J.C.BUFTON,S.PICAUD, JRNL AUTH 2 J.A.WARD,C.ROGERS,C.SUEBSUWONG,S.NIKHAR,G.D.CUNY,K.V.HUBER, JRNL AUTH 3 P.FILIPPAKOPOULOS,A.N.BULLOCK,A.DEGTEREV,M.GYRD-HANSEN JRNL TITL SMALL MOLECULE INHIBITORS REVEAL AN INDISPENSABLE JRNL TITL 2 SCAFFOLDING ROLE OF RIPK2 IN NOD2 SIGNALING. JRNL REF EMBO J. V. 37 2018 JRNL REFN ESSN 1460-2075 JRNL PMID 30026309 JRNL DOI 10.15252/EMBJ.201899372 REMARK 2 REMARK 2 RESOLUTION. 3.26 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX (1.13_2998: ???) REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 3.26 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 39.66 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.340 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.5 REMARK 3 NUMBER OF REFLECTIONS : 10834 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.231 REMARK 3 R VALUE (WORKING SET) : 0.229 REMARK 3 FREE R VALUE : 0.271 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.980 REMARK 3 FREE R VALUE TEST SET COUNT : 539 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 10.0000 - 5.1733 0.99 2679 138 0.2087 0.2294 REMARK 3 2 5.1733 - 4.1070 0.99 2570 138 0.2120 0.2770 REMARK 3 3 4.1070 - 3.5881 1.00 2535 123 0.2490 0.3085 REMARK 3 4 3.5881 - 3.2601 0.99 2511 140 0.3244 0.3642 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : NULL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.520 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 31.340 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.003 4748 REMARK 3 ANGLE : 0.551 6467 REMARK 3 CHIRALITY : 0.042 721 REMARK 3 PLANARITY : 0.003 818 REMARK 3 DIHEDRAL : 19.904 2857 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 6FU5 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 26-FEB-18. REMARK 100 THE DEPOSITION ID IS D_1200008934. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 30-APR-17 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : DIAMOND REMARK 200 BEAMLINE : I04 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9795 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 6M-F REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XIA2 REMARK 200 DATA SCALING SOFTWARE : XIA2 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 10837 REMARK 200 RESOLUTION RANGE HIGH (A) : 3.260 REMARK 200 RESOLUTION RANGE LOW (A) : 39.660 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.5 REMARK 200 DATA REDUNDANCY : 6.000 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 7.1200 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 3.26 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 3.38 REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: 4C8B REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 46.12 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.28 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 150 NL SITTING DROPS CONTAINING 50 NL REMARK 280 PROTEIN AND 100 NL OF A RESERVOIR SOLUTION CONTAINING 0.2 M REMARK 280 POTASSIUM FORMATE AND 20% (W/V) PEG3350, VAPOR DIFFUSION, REMARK 280 SITTING DROP, TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 37.89500 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 35.72500 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 61.35500 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 35.72500 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 37.89500 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 61.35500 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 3880 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 25340 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -25.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 SER A 1 REMARK 465 MET A 2 REMARK 465 GLY A 3 REMARK 465 GLU A 4 REMARK 465 HIS A 50 REMARK 465 ILE A 51 REMARK 465 HIS A 52 REMARK 465 SER A 168 REMARK 465 LYS A 169 REMARK 465 TRP A 170 REMARK 465 ARG A 171 REMARK 465 MET A 172 REMARK 465 MET A 173 REMARK 465 SER A 174 REMARK 465 LEU A 175 REMARK 465 SER A 176 REMARK 465 GLN A 177 REMARK 465 SER A 178 REMARK 465 ARG A 179 REMARK 465 SER A 180 REMARK 465 SER A 181 REMARK 465 LYS A 182 REMARK 465 SER A 183 REMARK 465 ALA A 184 REMARK 465 PRO A 185 REMARK 465 GLU A 186 REMARK 465 GLY A 187 REMARK 465 GLY A 201 REMARK 465 GLN A 202 REMARK 465 LYS A 203 REMARK 465 SER A 204 REMARK 465 ARG A 205 REMARK 465 ALA A 206 REMARK 465 SER A 316 REMARK 465 VAL A 317 REMARK 465 SER B 1 REMARK 465 MET B 2 REMARK 465 GLY B 3 REMARK 465 GLU B 4 REMARK 465 ILE B 51 REMARK 465 HIS B 52 REMARK 465 THR B 53 REMARK 465 PRO B 54 REMARK 465 GLY B 166 REMARK 465 LEU B 167 REMARK 465 SER B 168 REMARK 465 LYS B 169 REMARK 465 TRP B 170 REMARK 465 ARG B 171 REMARK 465 MET B 172 REMARK 465 MET B 173 REMARK 465 SER B 174 REMARK 465 LEU B 175 REMARK 465 SER B 176 REMARK 465 GLN B 177 REMARK 465 SER B 178 REMARK 465 ARG B 179 REMARK 465 SER B 180 REMARK 465 SER B 181 REMARK 465 LYS B 182 REMARK 465 SER B 183 REMARK 465 ALA B 184 REMARK 465 PRO B 185 REMARK 465 GLU B 186 REMARK 465 GLY B 187 REMARK 465 VAL B 317 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ARG A 22 CG CD NE CZ NH1 NH2 REMARK 470 ARG A 26 CG CD NE CZ NH1 NH2 REMARK 470 LYS A 61 CG CD CE NZ REMARK 470 ARG A 109 CG CD NE CZ NH1 NH2 REMARK 470 LEU A 167 CG CD1 CD2 REMARK 470 LEU A 314 CG CD1 CD2 REMARK 470 GLN A 315 CG CD OE1 NE2 REMARK 470 TYR B 23 CG CD1 CD2 CE1 CE2 CZ OH REMARK 470 ARG B 26 CG CD NE CZ NH1 NH2 REMARK 470 HIS B 50 CG ND1 CD2 CE1 NE2 REMARK 470 LEU B 55 CG CD1 CD2 REMARK 470 ARG B 65 CG CD NE CZ NH1 NH2 REMARK 470 GLN B 202 CG CD OE1 NE2 REMARK 470 LYS B 203 CG CD CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 OH TYR B 192 OE1 GLU B 221 2.02 REMARK 500 O PRO A 141 O HOH A 501 2.09 REMARK 500 OE2 GLU A 196 NH1 ARG A 280 2.18 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 20 50.00 72.25 REMARK 500 ARG A 109 60.06 -112.32 REMARK 500 HIS A 145 19.06 58.15 REMARK 500 ASP A 146 71.92 -170.32 REMARK 500 ASP A 155 -165.83 -79.50 REMARK 500 ASP A 164 56.82 73.17 REMARK 500 ASP B 20 47.47 70.19 REMARK 500 ARG B 109 59.12 -112.93 REMARK 500 ASP B 146 69.59 -169.62 REMARK 500 ASP B 155 -168.13 -78.78 REMARK 500 ASP B 164 59.18 72.98 REMARK 500 PRO B 200 94.15 -61.21 REMARK 500 GLN B 315 72.55 43.00 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue E7N A 400 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue E7N B 400 DBREF 6FU5 A 3 317 UNP O43353 RIPK2_HUMAN 3 317 DBREF 6FU5 B 3 317 UNP O43353 RIPK2_HUMAN 3 317 SEQADV 6FU5 SER A 1 UNP O43353 EXPRESSION TAG SEQADV 6FU5 MET A 2 UNP O43353 EXPRESSION TAG SEQADV 6FU5 SER B 1 UNP O43353 EXPRESSION TAG SEQADV 6FU5 MET B 2 UNP O43353 EXPRESSION TAG SEQRES 1 A 317 SER MET GLY GLU ALA ILE CYS SER ALA LEU PRO THR ILE SEQRES 2 A 317 PRO TYR HIS LYS LEU ALA ASP LEU ARG TYR LEU SER ARG SEQRES 3 A 317 GLY ALA SER GLY THR VAL SER SER ALA ARG HIS ALA ASP SEQRES 4 A 317 TRP ARG VAL GLN VAL ALA VAL LYS HIS LEU HIS ILE HIS SEQRES 5 A 317 THR PRO LEU LEU ASP SER GLU ARG LYS ASP VAL LEU ARG SEQRES 6 A 317 GLU ALA GLU ILE LEU HIS LYS ALA ARG PHE SER TYR ILE SEQRES 7 A 317 LEU PRO ILE LEU GLY ILE CYS ASN GLU PRO GLU PHE LEU SEQRES 8 A 317 GLY ILE VAL THR GLU TYR MET PRO ASN GLY SER LEU ASN SEQRES 9 A 317 GLU LEU LEU HIS ARG LYS THR GLU TYR PRO ASP VAL ALA SEQRES 10 A 317 TRP PRO LEU ARG PHE ARG ILE LEU HIS GLU ILE ALA LEU SEQRES 11 A 317 GLY VAL ASN TYR LEU HIS ASN MET THR PRO PRO LEU LEU SEQRES 12 A 317 HIS HIS ASP LEU LYS THR GLN ASN ILE LEU LEU ASP ASN SEQRES 13 A 317 GLU PHE HIS VAL LYS ILE ALA ASP PHE GLY LEU SER LYS SEQRES 14 A 317 TRP ARG MET MET SER LEU SER GLN SER ARG SER SER LYS SEQRES 15 A 317 SER ALA PRO GLU GLY GLY THR ILE ILE TYR MET PRO PRO SEQRES 16 A 317 GLU ASN TYR GLU PRO GLY GLN LYS SER ARG ALA SER ILE SEQRES 17 A 317 LYS HIS ASP ILE TYR SER TYR ALA VAL ILE THR TRP GLU SEQRES 18 A 317 VAL LEU SER ARG LYS GLN PRO PHE GLU ASP VAL THR ASN SEQRES 19 A 317 PRO LEU GLN ILE MET TYR SER VAL SER GLN GLY HIS ARG SEQRES 20 A 317 PRO VAL ILE ASN GLU GLU SER LEU PRO TYR ASP ILE PRO SEQRES 21 A 317 HIS ARG ALA ARG MET ILE SER LEU ILE GLU SER GLY TRP SEQRES 22 A 317 ALA GLN ASN PRO ASP GLU ARG PRO SER PHE LEU LYS CYS SEQRES 23 A 317 LEU ILE GLU LEU GLU PRO VAL LEU ARG THR PHE GLU GLU SEQRES 24 A 317 ILE THR PHE LEU GLU ALA VAL ILE GLN LEU LYS LYS THR SEQRES 25 A 317 LYS LEU GLN SER VAL SEQRES 1 B 317 SER MET GLY GLU ALA ILE CYS SER ALA LEU PRO THR ILE SEQRES 2 B 317 PRO TYR HIS LYS LEU ALA ASP LEU ARG TYR LEU SER ARG SEQRES 3 B 317 GLY ALA SER GLY THR VAL SER SER ALA ARG HIS ALA ASP SEQRES 4 B 317 TRP ARG VAL GLN VAL ALA VAL LYS HIS LEU HIS ILE HIS SEQRES 5 B 317 THR PRO LEU LEU ASP SER GLU ARG LYS ASP VAL LEU ARG SEQRES 6 B 317 GLU ALA GLU ILE LEU HIS LYS ALA ARG PHE SER TYR ILE SEQRES 7 B 317 LEU PRO ILE LEU GLY ILE CYS ASN GLU PRO GLU PHE LEU SEQRES 8 B 317 GLY ILE VAL THR GLU TYR MET PRO ASN GLY SER LEU ASN SEQRES 9 B 317 GLU LEU LEU HIS ARG LYS THR GLU TYR PRO ASP VAL ALA SEQRES 10 B 317 TRP PRO LEU ARG PHE ARG ILE LEU HIS GLU ILE ALA LEU SEQRES 11 B 317 GLY VAL ASN TYR LEU HIS ASN MET THR PRO PRO LEU LEU SEQRES 12 B 317 HIS HIS ASP LEU LYS THR GLN ASN ILE LEU LEU ASP ASN SEQRES 13 B 317 GLU PHE HIS VAL LYS ILE ALA ASP PHE GLY LEU SER LYS SEQRES 14 B 317 TRP ARG MET MET SER LEU SER GLN SER ARG SER SER LYS SEQRES 15 B 317 SER ALA PRO GLU GLY GLY THR ILE ILE TYR MET PRO PRO SEQRES 16 B 317 GLU ASN TYR GLU PRO GLY GLN LYS SER ARG ALA SER ILE SEQRES 17 B 317 LYS HIS ASP ILE TYR SER TYR ALA VAL ILE THR TRP GLU SEQRES 18 B 317 VAL LEU SER ARG LYS GLN PRO PHE GLU ASP VAL THR ASN SEQRES 19 B 317 PRO LEU GLN ILE MET TYR SER VAL SER GLN GLY HIS ARG SEQRES 20 B 317 PRO VAL ILE ASN GLU GLU SER LEU PRO TYR ASP ILE PRO SEQRES 21 B 317 HIS ARG ALA ARG MET ILE SER LEU ILE GLU SER GLY TRP SEQRES 22 B 317 ALA GLN ASN PRO ASP GLU ARG PRO SER PHE LEU LYS CYS SEQRES 23 B 317 LEU ILE GLU LEU GLU PRO VAL LEU ARG THR PHE GLU GLU SEQRES 24 B 317 ILE THR PHE LEU GLU ALA VAL ILE GLN LEU LYS LYS THR SEQRES 25 B 317 LYS LEU GLN SER VAL HET E7N A 400 65 HET E7N B 400 65 HETNAM E7N ~{N}-[5-[2-AZANYL-5-(4-PIPERAZIN-1-YLPHENYL)PYRIDIN-3- HETNAM 2 E7N YL]-2-METHOXY-PHENYL]PROPANE-1-SULFONAMIDE FORMUL 3 E7N 2(C25 H31 N5 O3 S) FORMUL 5 HOH *9(H2 O) HELIX 1 AA1 PRO A 14 HIS A 16 5 3 HELIX 2 AA2 LEU A 56 ALA A 73 1 18 HELIX 3 AA3 SER A 102 ARG A 109 1 8 HELIX 4 AA4 ALA A 117 ASN A 137 1 21 HELIX 5 AA5 PRO A 194 TYR A 198 5 5 HELIX 6 AA6 ILE A 208 ARG A 225 1 18 HELIX 7 AA7 ASN A 234 GLN A 244 1 11 HELIX 8 AA8 HIS A 261 TRP A 273 1 13 HELIX 9 AA9 ASN A 276 ARG A 280 5 5 HELIX 10 AB1 SER A 282 ARG A 295 1 14 HELIX 11 AB2 GLU A 298 GLN A 315 1 18 HELIX 12 AB3 PRO B 14 HIS B 16 5 3 HELIX 13 AB4 LEU B 56 ALA B 73 1 18 HELIX 14 AB5 SER B 102 ARG B 109 1 8 HELIX 15 AB6 ALA B 117 ASN B 137 1 21 HELIX 16 AB7 PRO B 194 TYR B 198 5 5 HELIX 17 AB8 ILE B 208 ARG B 225 1 18 HELIX 18 AB9 ASN B 234 GLN B 244 1 11 HELIX 19 AC1 HIS B 261 TRP B 273 1 13 HELIX 20 AC2 ASN B 276 ARG B 280 5 5 HELIX 21 AC3 SER B 282 ARG B 295 1 14 HELIX 22 AC4 GLU B 298 LEU B 314 1 17 SHEET 1 AA1 2 CYS A 7 ALA A 9 0 SHEET 2 AA1 2 CYS B 7 ALA B 9 -1 O SER B 8 N SER A 8 SHEET 1 AA2 5 LEU A 18 GLY A 27 0 SHEET 2 AA2 5 GLY A 30 HIS A 37 -1 O ARG A 36 N ALA A 19 SHEET 3 AA2 5 GLN A 43 HIS A 48 -1 O HIS A 48 N THR A 31 SHEET 4 AA2 5 LEU A 91 GLU A 96 -1 O THR A 95 N ALA A 45 SHEET 5 AA2 5 ILE A 81 ASN A 86 -1 N CYS A 85 O GLY A 92 SHEET 1 AA3 2 LEU A 153 LEU A 154 0 SHEET 2 AA3 2 VAL A 160 LYS A 161 -1 O LYS A 161 N LEU A 153 SHEET 1 AA4 5 LEU B 18 GLY B 27 0 SHEET 2 AA4 5 GLY B 30 HIS B 37 -1 O VAL B 32 N SER B 25 SHEET 3 AA4 5 GLN B 43 HIS B 48 -1 O VAL B 46 N SER B 33 SHEET 4 AA4 5 LEU B 91 GLU B 96 -1 O THR B 95 N ALA B 45 SHEET 5 AA4 5 ILE B 81 ASN B 86 -1 N CYS B 85 O GLY B 92 SHEET 1 AA5 2 LEU B 153 LEU B 154 0 SHEET 2 AA5 2 VAL B 160 LYS B 161 -1 O LYS B 161 N LEU B 153 CISPEP 1 THR A 139 PRO A 140 0 -0.19 CISPEP 2 THR B 139 PRO B 140 0 -1.39 SITE 1 AC1 15 LEU A 24 SER A 25 SER A 29 VAL A 32 SITE 2 AC1 15 ALA A 45 LYS A 47 GLU A 66 THR A 95 SITE 3 AC1 15 GLU A 96 MET A 98 GLU A 105 GLN A 150 SITE 4 AC1 15 LEU A 153 ALA A 163 ASP A 164 SITE 1 AC2 14 LEU B 24 SER B 25 VAL B 32 ALA B 45 SITE 2 AC2 14 LYS B 47 GLU B 66 THR B 95 GLU B 96 SITE 3 AC2 14 MET B 98 GLU B 105 GLN B 150 ASN B 151 SITE 4 AC2 14 LEU B 153 ASP B 164 CRYST1 75.790 122.710 71.450 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.013194 0.000000 0.000000 0.00000 SCALE2 0.000000 0.008149 0.000000 0.00000 SCALE3 0.000000 0.000000 0.013996 0.00000